IRCT20190524043684N1
Recruiting
Phase 3
Evaluation of therapeutic effect of Tiotropium Bromide in early stages of chronic obstructive pulmonary disease in patients of subspecialty clinics of Isfahan university of medical science in 2018 - 2019
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Esfahan University of Medical Sciences
- Enrollment
- 92
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age between 40 \- 80 years
- •History of COPD stage GOLD 1 , 2
- •FEV1 to FVC ratio less than 0\.7 after bronchodilator use
Exclusion Criteria
- •Not signing informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
The effectiveness of Tiotropium bromide in patients with severe asthmaIRCT20181015041353N1Zahedan University of Medical Sciences60
Completed
Not Applicable
Efficacy of Tiotropium bromide (Spiriva 2.5 microgram Respimat 60 puffs) for chronic asthmatic cough refractory to intensive therapiesasthmaJPRN-UMIN000021064agoya City University Dept of Respiratory Medicine, Allergy and Clinical Immunology58
Completed
Not Applicable
Comparison of the effect of tiotropium monotherapy versus tiotropium and indacaterol combination therapy in patients with chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease (COPD)JPRN-UMIN000009077Department of Respiratory Medicine, Chiba-Hokusoh Hospital, Nippon Medical School60
Active, not recruiting
Not Applicable
Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation-TIBROMUC- - TIBROMUCAnticholinergic bronchodilators, such as ipratropium bromide, may be used in combination with beta adrenergic agonists as SAlbutamol to produce bronchodilation in excess of that achieved by either agent alone.Therefore we will treat both study arms with salbutamol. One group A will receive tiotropium bromide with salbutamol, while the other group B will receive salbutamol.MedDRA version: 8.1Level: LLTClassification code 10010952Term: COPDEUCTR2006-005819-10-DEPhilipps-University Marburg
Completed
Not Applicable
Efficacy evaluation of Tiotropium Respimat with AeroChamber PlusCOPDJPRN-UMIN000013980Hamamatsu medical center20